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Refractory angina pectoris is defined as a chronic debilitating condition characterized by 
the presence of chronic anginal symptoms due to a severe obstructive and/or diffuse 
coronary artery disease that cannot be controlled by the combination of medical therapy 
and/or revascularization (percutaneous or surgical). In addition, the presence of myocar-
dial ischemia as a cause of the symptoms must have been documented. The coronary 
sinus reducer (CSR) is a recently introduced percutaneous device to treat patients with 
severe anginal symptoms refractory to optimal medical therapy and not amenable to 
conventional revascularization. The purpose of this review is to describe the current 
evidence from available studies measuring the clinical effect of the CSR implantation on 
the health and well-being of patients with refractory angina.
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introdUCtion
Refractory angina pectoris is defined as a chronic debilitating condition characterized by the 
presence of anginal symptoms due to a severe obstructive and/or diffuse coronary artery disease 
(CAD) that cannot be controlled by the combination of medical therapy and/or revascularization 
(percutaneous or surgical).
Despite the numerous methods of treatment of CAD, a growing number of patients (10–15%) 
with severe chronic ischemic heart disease continue to have refractory angina not susceptible to 
therapeutic alternatives (1). These patients are often labeled “end-stage” or “no-option” patients and 
represent a complex and heterogeneous population (2, 3). The factors responsible for the heterogene-
ity of these patients are the severity and frequency of angina [measured with the class of angina of 
the Canadian Cardiovascular Society (CCS)], the extent of CAD, the presence of recurrent coronary 
restenosis after percutaneous treatment, the presence of an occluded bypass graft in post-coronary 
artery bypass graft (CABG) surgery patients, and the presence of coronary chronic total occlusions. 
These may explain the difficulties encountered in assessing the effectiveness and mechanisms of 
action of various proposed therapeutic alternatives (4–6).
There are limited data regarding the natural history and predictors of mortality for patients with 
refractory angina (7). A retrospective study of the Cleveland Clinic in 500 consecutive patients 
undergoing cardiac catheterization showed that 59 patients had ischemia but were not susceptible 
FiGUre 1 | the reducer device. Above – expanded device. Below – 
expanded device mounted on the delivery balloon with their hourglass shape.
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to revascularization (8). The 1-year mortality in this small cohort 
of patients was 17% and has led many to believe that patients with 
refractory angina are at high risk of mortality (8). A recent study 
at Duke University investigated a database of 1908 consecutive 
patients with refractory angina who underwent catheterization 
(7). The analysis of mortality rates has shown that patients with 
clinically stable CAD who were under optimal medical therapy 
had similar mortality but a high incidence of re-hospitalization 
over the next 3 years of follow-up (7, 9). Moreover, patients with 
refractory angina use many anti-ischemic medications, experi-
ence impaired quality of life because of debilitating symptoms, 
and are relatively young (60–65 years) (10). These results indicate 
the need for new therapies targeting the reduction of symptoms 
in this population, taking into account also the potential impact 
in terms of health-care consumption and cost (6). Several anti-
ischemic therapies (e.g., novel medical treatment such as ivabra-
dine and ranolazine, extracorporeal shockwave therapy, spinal 
cord stimulation, transmyocardial laser revascularization, gene 
therapy, and cell therapy) have been investigated, none of which 
has become mainstream (5, 11). Currently, treatment options for 
this patient group are limited mainly to traditional anti-anginal 
therapy and to modification of risk factors (12, 13).
Animal studies have revealed that the increase of venous 
pressure at the level of the coronary sinus (CS) is able to reduce 
myocardial ischemia leading to a redistribution of blood from 
the non-ischemic to the ischemic territories (14–17). Recently, 
the coronary sinus reducer (CSR) has been introduced in clinical 
practice as a new device-based treatment for patients with refrac-
tory angina (18, 19). Implantation of the CSR is the percutaneous 
equivalent of surgical CS narrowing as described by Beck et al. 
(20, 21) and shows promise as treatment for refractory angina. 
Although Beck-II procedure has little in common with the CSR 
as the first is a surgical operation, meanwhile the second is a 
percutaneous intervention; however, the concept of narrowing 
the CS is similar, and this makes the two procedures conceptu-
ally comparable (interestingly both procedures aim at a residual 
lumen diameter in the CS around 3 mm).
deViCe and iMpLantation proCedUre
The CSR is an endoluminal device, which consists of a stainless 
steel stent in the shape of an hourglass mounted on an expandable 
balloon with the same shape once inflated (Figure 1). The device 
is intended to be implanted percutaneously into the CS to create 
a controlled narrowing of the CS. The CS is the final step in the 
cardiac venous drainage; thus, a controlled stenosis at this level 
can lead to a slight increase of the coronary venous pressure. As 
demonstrated in a preclinical study, the mean pressure gradient 
assessed across the reducer was 3.71 ± 1.75 mmHg immediately 
after implantation (18). The device is provided in a single model 
(“one-size-fits-all” design) and is suitable for a wide range of 
anatomies of the CS (from a minimum diameter of 9  mm to 
a maximum of 14  mm). The device received CE approval in 
November 2011 for the treatment of refractory angina.
The implantation is performed under fluoroscopic guidance 
through percutaneous approach from the right-jugular vein 
under local anesthesia and through venapuncture. This approach 
is more practicle than femoral approach because via the latter, 
the sharp bend from the inferior vena cava to the coronary sinus 
would be much more difficult to tackle than the bend from 
the superior vena cava to the coronary sinus from the jugular 
vein. Furthermore, a 6-Fr diagnostic catheter (Multipurpose or 
Amplatz left) is used to measure the right ventricular pressure 
(which must be less than 15  mmHg, to avoid treating patients 
with uncontrolled heart failure) and to selectively cannulate the 
CS. Subsequently to contrast injection to assess whether the CS 
is suitable for implantation, a 9-Fr guiding catheter is advanced 
in the distal CS with the support of the 6-Fr diagnostic catheter 
(“mother-and-child” technique). Once the 9-Fr guiding catheter 
is positioned as distally as possible in the CS, the 6-Fr diagnostic 
catheter is retracted and the reducer is advanced inside the 9-Fr 
guiding up to the place chosen for the implant. The 9-Fr guiding 
catheter is then retracted in order to expose the reducer. The 
next step is the inflation of the balloon on which the reducer 
is mounted; the pressure ranges from 2 to 6 atm depend on the 
diameter of the CS. An injection of additional contrast during 
inflation of the reducer helps evaluate a possible slight oversiz-
ing of the reducer as compared to the diameter of the CS. After 
deflation, the balloon is gently retrieved in order to avoid the 
displacement of the reducer. A final angiogram is then performed 
to evaluate the correct position of the device and the absence of 
any complications such as perforations (Figure 2). The procedure 
is performed in an outpatient setting. Patients are discharged after 
a few hours, upon confirmation that the access site (jugular vein) 
is properly closed. After the procedure, dual antiplatelet therapy 
with aspirin and clopidogrel is recommended for a month (as for 
bare metal stents).
saFety and eFFiCaCy perForManCes
In various studies, the CSR was safely implanted percutaneously 
via the jugular vein, and it was associated with an improvement 
FiGUre 2 | angiographic image of the coronary sinus (a). Deployment 
of the reducer in the coronary sinus (B). Final angiographic control after 
reducer implantation (C).
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in anginal symptoms and also in the parameters of ischemia, in 
patients with refractory angina, who were not candidates for 
any form of revascularization (18, 22–25). These results support 
further evaluation of the CSR as an alternative treatment for 
patients with chronic refractory angina, who are not candidates 
for coronary revascularization.
The first study was a multicenter, non-randomized, prospec-
tive, and first-in-man study, which revealed that the use of the 
CSR in patients with refractory angina was safe and feasible (18). 
In particular, it involved 15 patients with refractory angina treated 
with the device. The installation of all devices was completed 
successfully. No procedural adverse events occurred. Most of the 
patients (85%) significantly improved their anginal symptoms, 
and also, the extent and severity of myocardial ischemia detected 
by dobutamine echocardiography significantly reduced in 8 
out of 13 patients (18). Also, there was a medically significant 
reduction in extent and severity of myocardial ischemia in 4 out 
of 10 patients detected by Thallium SPECT studies (18). Clinical 
improvement was reported by the patients a few weeks after the 
procedure and not immediately after implantation. These results 
support the hypothesis that the controlled diameter reduction 
of the CS accompanied by an increase in venous pressure may 
improve myocardial perfusion during stress with consequent 
reduction of ischemia (18).
Another study evaluated the clinical results during 6 months 
of follow-up among 21 patients treated with the reducer (23). The 
results came from two centers (Antwerp Cardiovascular Center, 
Antwerp, Belgium, and Tel Aviv Medical Center, Tel Aviv, Israel), 
where the device is currently used to treat patients with refrac-
tory angina, with objective evidence of myocardial ischemia and 
ejection fraction ≥25%, who were not candidates for surgical or 
percutaneous coronary revascularization. The results demon-
strate that the implant of the CSR was associated with a significant 
improvement in angina class (CCS class decreased significantly 
6  months after the implant from an average of 3.3  ±  0.6 to 
2.0 ± 1.0). In 85% of the cases, the improvement in functional 
CCS class was significantly observed. Clinical improvement was 
reported starting a few weeks after the procedure and maintained 
at follow-up.
The third study is the recently published multicenter rand-
omized COronary SInus Reducer for treatment of refractory 
Angina (COSIRA) sham-controlled trial, which confirmed the 
efficacy of CS narrowing by reducer implantation as treatment 
for refractory angina (24). The study was conducted in 11 clinical 
centers and enrolled 104 patients. All patients underwent cath-
eterization for angiography of the CS, and once confirmed that 
the vessel was treatable with the reducer, patients were randomi-
zation. Half of the patients underwent CSR implantation; the 
other half was not treated and formed the sham-control group. 
Dual antiplatelet therapy was given for at least 1 week before the 
procedure and for 6 months after the procedure in the two study 
groups. Care was taken to maintain patients blinded to the treat-
ment. In addition, the clinical evaluation of patients before and 
after the treatment was performed by cardiologists not involved 
with the procedure and not informed about the treatment 
received by the patients themselves. So, the study can be called 
double-blind because patients and physicians that assessed the 
clinical status of the patients did not know the therapy performed 
during the procedure. A total of 18 out of 52 patients in the 
treatment group and 8 out of 52 in the control group had an 
improvement of at least 2 CCS classes, which was the primary 
endpoint of the study (24). Thus, a significant improvement in at 
least two CCS classes (35 versus 15%, p = 0.02) was noted with 
the CSR. Moreover, in the treatment group, 71% of patients (37 
of 52 patients) had an improvement of at least one CCS class, 
compared to 42% (22 of 52) in the control group (p = 0.003). 
In addition, quality of life was improved in the CSR group as 
compared to the control group. No significant differences were 
observed between the two groups with respect to changes in the 
secondary endpoints, such as the duration of exercise and time 
to ST segment changes during ergometry, or the variation of the 
indices of ischemia by stress echocardiography or myocardial 
scintigraphy (24).
From 2014, the CSR stent is regularly used in our institution 
as a treatment option in clinical practice for the treatment of 
refractory angina. In 2014, 23 patients have been treated and a 
retrospective registry has been set up to assess the results of the 
implant of the reducer in these real-world patients (25). Patients 
were included based on the following criteria: (1) symptomatic 
angina CCS classes 2–4, despite optimal medical therapy; (2) 
evidence of inducible myocardial ischemia, caused by at least one 
of the following tests – cardiovascular cycle ergometer exercise 
test, myocardial scintigraphy, stress echocardiogram, or stress 
magnetic resonance imaging; (3) CAD not suitable for revascu-
larization according to the decision of the Heart team. Unlike 
the COSIRA (24) in which only patients were included with a 
positive dobutamine stress echocardiography, in this registry, all 
forms of proven inducible ischemia have been accepted for the 
inclusion of patients. In line with previous studies (18, 24), the 
CSR implantation in these real-world patients was safe with no 
procedural-related complications. The majority of patients (74%) 
experienced a significant reduction in anginal symptoms few 
weeks following the procedure (25).
Theoretically, several complications may occur during or after 
the CSR implantation (CS dissection during catheter or wire 
manipulation, direct or late device migration, cardiac tamponade 
due to CS rapture); however, up to now, there are no data exist 
regarding the complications. Up to now, no cases of device occlu-
sion has been shown during follow-up in all the patients. Also, no 
atrial arrhythmias have been described. The atrium does not get 
the influence of the device in terms of increased pressure, indeed 
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the increase in pressure occurs only in the coronary vascular tree 
and that seems to be the mechanism of action.
MeCHanisM oF aCtion
The suggested anti-ischemic effect of the CSR is based on 
the hypothesis first described by Camici et  al. (2), and the 
first clinical results of the CSR implantation in human were 
published by Banai et  al. (18). In a normal heart, during 
exercise, there is a sympathetic-mediated vasoconstriction of 
the sub-epicardial vessels, which leads to an increase of blood 
flow to the sub-endocardial capillaries (26). In patients with 
obstructive CAD, this physiological compensation mechanism 
is dysfunctional (27). In addition, in the presence of ischemia, 
altered contractility and the high left ventricular end-diastolic 
pressure exert an external pressure on the sub-endocardial 
capillaries, which further increases the flow resistance toward 
the sub-endocardium, leading to a vicious circle that deter-
mines a worsening of sub-endocardial ischemia. High pressure 
upstream of the CS determines an increase of the pressure in the 
capillaries and venules, which will result in a slight expansion 
of the diameter of the capillaries and a significant reduction of 
the flow resistance. The resulting reduction in sub-endocardial 
capillary resistance subsequent to reducer implantation involves 
the rebalancing of the ratio between sub-epicardial and sub-
endocardial blood flow that is pathologically impaired in 
ischemic myocardium (24). The result of this process is thus 
an improvement in the flow of blood to the sub-endocardial 
ischemic layers (28). This effect appears to take action in the first 
few months after reducer implantation as the stenosis becomes 
effective only once the device is covered with neointimal tissue, 
and this endothelialization process occurs in a few months 
(18, 24). Interestingly, porcine studies demonstrated that the 
pressure gradient across the reducer device decreases during 
6  months follow-up (18).
The second potential mechanism of action is linked to the pos-
sible angiogenic effect of the device (29). In the early 90s, scientific 
research introduced new treatments for retrograde reperfusion of 
acutely ischemic myocardium through a kind of small balloon 
pump inserted into the CS, assuming that this device could 
reduce the post-infarction damage increasing venous pressure 
downstream of the ischemic territory (17). Histological findings 
of these studies suggest the possible intra-myocardial and epicar-
dial angiogenesis due to proliferation of small- and medium-sized 
arteries that constitute the collateral circulation of the ischemic 
territory. However, these findings are still debated (29). Moreover, 
despite the careful selection of patients, the results may be influ-
enced by a placebo effect because of the subjective nature of the 
major endpoint assessed. Future studies with more patients and 
long-term follow-up are needed to explore any possible objective 
effect of the CSR.
tHe Cs redUCer as a treatMent 
option For reFraCtory anGina
The development of new therapies for patients with refractory 
angina should focus not only on reducing the risk of death 
and myocardial infarction but also (and perhaps especially) on 
alleviation of angina and improvement of quality of life. In fact, 
the prevalence of refractory angina continues to increase in rela-
tion to the increase in survival of patients with ischemic heart 
disease and the aging of the population. Although data on the 
incidence of refractory angina are scarce, in about 10–15% of the 
cases, patients with stable angina and evidence of ischemia are 
not amenable to percutaneous or surgical revascularization (1). 
These patients are mainly debilitated by poor quality of life and a 
high level of depression and anxiety because of their disease (30). 
Recent studies have highlighted the need to improve the quality 
of life of these patients, even more as there is growing evidence 
that the death rate seems to be similar to, and not higher than, 
other patients with stable CAD (31, 32). In order to improve 
the quality of life in patients with refractory angina reduction 
in anginal symptoms is an important goal. It is essential to 
emphasize that among the choices for alternative options to offer 
to patients with refractory angina, the CSR should be considered, 
because it is a secure device and apparently effective in reducing 
anginal symptoms and in improving the quality of life in this 
category of patients (24). Expected data from ongoing studies 
among these patients will further evaluate the impact of CSR on 
angina symptoms and quality of life (https://ClinicalTrials.gov, 
NCT02710435/NCT01566175). Furthermore, future studies are 
needed to investigate and confirm the mechanism of action of 
the CSR with the use of more accurate imaging techniques such 
as the use of SPECT or fMRI.
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